Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27806854 | 0.81 | ABAT (0.48) | LOXL2MAOBCA1CA2ARG2 | |
| SCHEMBL1805094 | 0.78 | ESR1 (0.48) | ALDH1A1CYP3A4TDP1MAOBCA1 | |
| SCHEMBL9841063 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP3A4GFERTSHRTDP1 | |
| SCHEMBL27614866 | 0.78 | ESR1 (0.48) | ALDH1A1CYP3A4TDP1MAOBCA1 | |
| SCHEMBL9841062 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP3A4GFERTSHRTDP1 | |
| SCHEMBL24042960 | 0.76 | IDO1 (0.43) | TSHRMAOBCA1CA2ARG2 | |
| SCHEMBL6029605 | 0.76 | ALDH1A1 (0.46) | ALDH1A1CYP3A4GFERTSHRTDP1 | |
| SCHEMBL7113395 | 0.76 | ALDH1A1 (0.46) | ALDH1A1CYP3A4GFERTSHRTDP1 | |
| SCHEMBL9047930 | 0.76 | IDO1 (0.43) | MAOBCA1CA2ARG2MEN1 | |
| SCHEMBL28478078 | 0.76 | AGXT (0.43) | TDP1MAOBCA1CA2ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858626-B2 | Enzyme inhibitor; antiinflammatory agents; osteoporosis | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | XUE CHU-BIAO (US) | 2003-07-24 | — | — | US | disclosed |
| US-6429213-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | disclosed |
| US-5811398-A | Platelet aggregation inhibitors containing C-terminal aminergic side chain amino acid residues | G. D. SEARLE & CO. (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0835265-A1 | PLATELET AGGREGATION INHIBITORS CONTAINING C-TERMINAL AMINERGIC SIDE CHAIN AMINO ACID RESIDUES | G.D. SEARLE & CO. (US) | 1998-04-15 | — | — | EP | disclosed |
| WO-1996032415-A1 | PLATELET AGGREGATION INHIBITORS CONTAINING C-TERMINAL AMINERGIC SIDE CHAIN AMINO ACID RESIDUES | G.D. SEARLE & CO. (US) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | MMP9, MMP2, MMP25 | ALDH1A1 621/4885CYP3A4 2541/4885GFER 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.